• Publications
  • Influence
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
TLDR
A small number of patients with type 2 diabetes mellitus have demonstrated reduced hospitalizations for heart failure with sodium-glucose co-transporter-2 inhibitors, and these trials suggest these drugs should be considered as potential treatments for HF. Expand
Relationship Between Anticoagulation Intensity and Thrombotic or Bleeding Outcomes Among Outpatients With Continuous-Flow Left Ventricular Assist Devices
TLDR
Thrombotic and bleeding outcomes in patients with continuous-flow left ventricular assist devices (CF-LVADs) are evaluated and target international normalized ratio (INR) values <2.0 increase the rate of thrombosis events occurring outside of the hospital among patients supported with CF- LVADs. Expand
Intra-Aortic Balloon Counterpulsation in Patients With Chronic Heart Failure and Cardiogenic Shock: Clinical Response and Predictors of Stabilization.
TLDR
Baseline measures of right and left ventricular cardiac power, reflecting work performed for a given flow and pressure, may allow clinicians to identify patients with sufficient contractile reserve who will be likely to stabilize with an IABP versus those who may need more aggressive ventricular support. Expand
Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction: A Secondary
TLDR
In serial health status evaluations of patients with HF, the most recent KCCQ score was most strongly associated with subsequent death and cardiovascular hospitalization in HFpEF and HFrEF, respectively. Expand
Global Outcome in Patients With Left Ventricular Assist Devices.
TLDR
Composite outcomes may better capture events that matter to patients with LVADs and thus support informed decisions about pursuing LVAD therapy. Expand
Systolic blood pressure on discharge after left ventricular assist device insertion is associated with subsequent stroke.
TLDR
In this large, CF-LVAD cohort, elevated SBP was independently associated with a greater risk of subsequent stroke, and management of hypertension is identified as a potential modifiable risk factor for reducing the incidence of stroke in patients supported by CF- LVAD. Expand
Usefulness of Psoas Muscle Area Determined by Computed Tomography to Predict Mortality or Prolonged Length of Hospital Stay in Patients Undergoing Left Ventricular Assist Device Implantation.
TLDR
It is demonstrated that sarcopenia as measured by psoas muscle area is associated with increased composite length of stay and mortality after LVAD implantation and may serve as correlate for frailty. Expand
Clinical outcomes associated with INTERMACS-defined right heart failure after left ventricular assist device implantation.
TLDR
A novel, fibrin-specific 99mTc small tetrameric probe offers the potential to detect, localize, and quantify intra-LVAD thrombus noninvasively and offers the opportunity to diagnose LVAD pump thrombosis at an earlier stage. Expand
Incidence and Predictors of Cognitive Decline in Patients with Left Ventricular Assist Devices
TLDR
Cognitive decline occurs commonly in patients in the year after LVAD and is associated with older age and destination therapy, which could have important implications for patient selection and improved communication of risks before LVAD implantation. Expand
Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure
TLDR
Among outpatients with HFrEF, women, blacks, Hispanics, and poorer patients had worse health status, which remained significant for women, Hispanics and richer patients in fully adjusted analyses, and suggests an opportunity to further optimize treatment to reduce these observed disparities. Expand
...
1
2
3
4
5
...